Gain Therapeutics (NASDAQ:GANX) Given New $8.00 Price Target at HC Wainwright

Gain Therapeutics (NASDAQ:GANX) had its price target reduced by HC Wainwright from $9.00 to $8.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on the stock. Chardan Capital restated a buy rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reissued an outperform rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Tuesday, April 23rd.

Gain Therapeutics Stock Up 3.4 %

Gain Therapeutics stock opened at $1.20 on Tuesday. The company’s 50-day moving average price is $2.12 and its two-hundred day moving average price is $3.23. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05. The stock has a market cap of $21.66 million, a price-to-earnings ratio of -0.80 and a beta of 0.35. Gain Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.33.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, analysts expect that Gain Therapeutics will post -1.11 EPS for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.